Psychedelics are powerful, mostly illegal, and not risk-free. That is exactly why rigorous research and honest education matter. Read the safety page
Last reviewed 2 October 2026
IRS-recognized 501(c)(3) public charityFree 17-chapter science bookDonor-supported, no industry funding
Our Approach
A different starting point
Today's psychedelic renaissance focuses almost entirely on treating illness. Metanoia prioritizes the everyday, healthy person, someone not seeking therapy, but aspiring to elevate their well-being, creativity, self-awareness, and potential, through a multidisciplinary research approach integrating genetics, chemistry, neuroscience, cultivation, therapy, and sex- and gender-based differences.
Multidisciplinary Research
Six integrated disciplines driving a 360° understanding
Neuroscience
How psychedelics, psilocybin, LSD, ayahuasca, iboga, affect brain activity, neuroplasticity, and cognition, in plain language.
Read moreClose
Classic psychedelics share a starting point at the serotonin 2A receptor. At the scale of the whole brain, the clearest shared finding in recent imaging is more communication between networks that usually keep apart, not the shutdown of a single network.
Plasticity is where the interest lies for healthy adults, and where caution is needed. A growth factor rose inside lab-grown human cells, but it did not change in the blood of healthy adults given LSD. What lasts, and whether it matters for growth, is still open.
Whether genetic factors shape how individuals respond to psychedelics, across the whole family, for personal development.
Read moreClose
Two questions: the genetics of the mushroom and the genetics of the person. The mushroom side is further along, and most commercial cultivars turn out to share identical psilocybin genes.
On the person side, we have not identified a human study that links a genetic variant to how strongly someone responds to a classic psychedelic. The enzymes and receptors involved are known, which makes this one of the clearest open questions in the field.
Studying natural sources, mushrooms, cacti, vines, and bark, as whole chemical systems, not single molecules.
Read moreClose
A natural source is a chemical system. Psilocybin comes with relatives such as psilocin, baeocystin and aeruginascin, and every plant in the family has its own alkaloids. Measuring them reliably is harder than it looks.
Whether the whole source acts differently from the pure molecule is open. Preliminary animal work hints at it, human validation is lacking, and the whole mushroom has not been shown to be better. It is different, and not yet properly studied.
How species, growing conditions, and handling shape a mushroom's real chemistry, and why every batch can differ.
Read moreClose
Psilocybin content differs between species, within a species and from batch to batch, and it shifts with how the mushroom is dried and stored. That makes cultivation a research variable, not a hobbyist footnote.
Research that does not record how its material was grown cannot be repeated. This discipline also carries our sustainability commitment: cultivable sources over threatened or wild ones.
How preparation, support, and integration are studied and reported, across every substance in the family.
Read moreClose
The molecule is only part of the story. Preparation, support during the experience and integration afterwards shape what happens, and researchers are only now learning to describe them precisely enough to compare.
Metanoia studies and documents this practice. We do not provide preparation, support, integration or therapy, and we do not supply any controlled substance.
How sex and gender shape psychedelic response, one of the least-studied questions in the field.
Read moreClose
Do these substances act differently in women and men, or across hormonal states? Women make up close to half of recent trial participants. The serious representation gap is ethnic.
What is missing is analysis by sex and hormonal state. Sex and gender are recorded as separate fields in the standards we build, and differences are reported wherever they appear, including when there are none.
The twelve dimensions of human potential our research sets out to understand, and measure.
12 dimensions
Turn the wheel, or tab through it, to read more.
Reviewed
Creativity
The largest controlled trials find no lasting creativity boost from psychedelics in healthy adults, only a temporary, two-sided shift in thinking style during the acute state.
No controlled trial found here shows natural psychedelics improving problem-solving in healthy adults, and several show a decline in convergent thinking during the acute state.
The most consistent controlled finding in healthy adults is a lower amygdala response to negative images during the acute state. No controlled trial has made resilience or emotion regulation its main question, and nobody has followed healthy participants through real setbacks.
No controlled trial in healthy adults has yet reported lasting change in social connection, and the two large uncontrolled surveys lost more than half of their participants before the key follow-up.
People say self-exploration is why they use psychedelics, but the direct test, a validated self-awareness measure against placebo in healthy adults, has not been run.
A few small placebo-controlled laboratory studies found higher self-rated emotional empathy for a few hours, one psilocybin result was not reproduced, and cognitive empathy did not improve. No controlled measurement beyond the session itself exists in healthy adults.
A single, well-supported high-dose session produces a durable, self-rated sense of meaning, but the standardized instruments alongside it mostly do not move, and repeated microdosing shows no consistent benefit over placebo.
Acute perceptual effects are the best established effects of the classic psychedelics, while performance on perceptual and timing tasks mostly gets worse during them. No study has followed perception in healthy adults afterward, so lasting change is untested.
In rodents, psychedelics change brain structure and speed up fear extinction. In healthy people the best-quantified result is acute, with slower reaction times and worse memory scores in proportion to dose, and no controlled study shows a lasting improvement.
Evidence that classic psychedelics raise mindfulness in healthy adults is thin and mixed. In the best controlled trials the result is small or absent once a placebo and the surrounding retreat are accounted for.
People who have used psychedelics score higher on nature relatedness, and small uncontrolled studies report rises, but no randomized, placebo-controlled study in healthy adults has tested the question.
No controlled study has measured leadership after a psychedelic in healthy adults. The nearest evidence concerns related traits such as openness and flexibility, and none of it was rated by the people a person leads.
Expanding human consciousness, studied rigorously, shared openly.
The Measurement Problem
Twelve dimensions, and no agreed way to measure them
Study after study measures growth in healthy adults with instruments built for illness, and almost none records what a person was seeking, or whether they found it, months later. Building that missing standard, openly and free to reuse, is Metanoia's central research project.
of U.S. adults aged 18 to 25 met survey criteria for a past-year major depressive episode in 2021, the highest rate of any adult age groupNIMH, from the 2021 National Survey on Drug Use and Health
~3 in 10
U.S. adults treated with medication for major depression meet criteria for treatment-resistant depression, meaning two or more adequate medication trials without response (30.9%, a claims-based estimate)Zhdanava et al., J Clin Psychiatry, 2021
Most
research still targets illness, not growth in healthy adults
Few
qualified, science-based frameworks for growth-focused use
9%
of U.S. adults 19 to 30 report past-year hallucinogen use, a five-year highNIDA/NIH, 2024
Shifting
motivations: from curiosity at first use to personal growth over timeKruger et al., 2025
PressThe Mushroom as a Chemical SystemBeyond a single molecule · 2026 edition
Public Education
We publish what we learn, free to everyone
Research only matters if people can use it. Alongside our guides and education pages, our first full-length open-access title explores psilocybin mushrooms not as one molecule but as a living chemical system: biosynthesis, the entourage of related compounds, dose and variability, cultivation, and the ethics of traditional knowledge. Rigorous for experts, clear for newcomers, and free for both.
17 chapters10 illustrationsReference edition in preparation
Today Metanoia is a California 501(c)(3) public charity, and nothing else: it leads research direction, public education, governance, and fundraising. Our long-term plan contemplates a separate for-profit research affiliate, limited in scope to contracted institutional research and funded by investment capital rather than donations. That affiliate has not been formed. Any future incentive for whoever leads it, including founder equity, would need independent review, a fair value, a cap, board supermajority approval, and public disclosure. None exists today.
All public education and fundraising benefits the nonprofit mission.
"The psychedelic renaissance is happening with or without proper guidance. Our choice is whether it unfolds safely, scientifically, and equitably, and whether it serves the everyday person seeking to thrive, not only the patient seeking a cure."
Metanoia is built around the science, not around personalities. You won't find our faces here, and that's on purpose.
Your gift fuels rigorous research and free public education that can help healthy adults thrive. Gifts may be deductible for federal income tax purposes, depending on the donor's own tax position.
